Vision Research Report, Recently Announced New Report on “erythropoietin drugs market – Global Industry Analysis, Market Size, Share, Growth, Trends, Region Outlook, And Segment Forecasts, 2021 – 2030″.
Global “Erythropoietin drugs market” Report 2021 covering manufacturers, regions, segments, forecast to 2030 is that the recent research report with correct information and extremely authentic info. The report provides insights on market share, market size, rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, and distributors. The Erythropoietin drugs research report focuses on the competitive surroundings that has section on company profile covering product specifications, geographical coverage, recent developments, revenue analysis, and market shares. what is more, the report offers strategic recommendations so as to help the consumers to align business goals.
The Erythropoietin drugs market revenue share is set to grow at a yearly rate of 21.5% during 2021-2030, while its valuation is Projected to jump from $ 17.4 Bn in 2020 to $27.4 Bn in 2030.
Get Sample Copy of This Report@ https://www.visionresearchreports.com/report/sample/37913
Report Highlights
Of the various drug classes, the biologics erythropoietin class held a dominant share as of 2020, owing to patent protection. Presence of large patient population and higher uptake of biologics are other contributing factors towards its dominance. In addition, the availability of very few biologics in the market has led to increased adoption. Furthermore, owing to its wide applications in the treatment of CKD, the biologics segment accounted for the majority of the revenue share.
The biologics segment is anticipated to lose its market share due to recent patent expiration of major brands such as Epogen. This drug lost its patent exclusivity in May 2015, which resulted in reduced sales revenue for its manufacturer company, Amgen Inc.
Biosimilars are expected to gain popularity in the near future for the treatment of anemic conditions. Biosimilars are easy to develop, cost-effective, and require less time for approval as compared to biologics. These associated advantages are expected to propel the segment growth throughout the forecast period.
Increasing investments in R&D for biosimilars, strong product pipeline, and collaborations between hospitals &manufactures for the adoption of EPO biosimilars are key market drivers for the growth of the biosimilar segment. The recent launch of erythropoietin biosimilars in the U.S. is further expected to showcase a paradigm shift in global EPO drugs from biologics to biosimilars.
In the product segment, Epoetin-alfa held a dominant share due to its wide adoption amongst healthcare professionals. This product was the first biologic to be approved by the U.S.FDA for the treatment of anemia resulting from CKD, cancer chemotherapy, and HIV treatment. Epoetin-alfa was patent-protected, which restricted the production of any other recombinant human erythropoietin drug and helped this segment dominate in 2020.
Epoetin-beta is a recombinant form of epoetin-alfa. This segment held a considerable share in the products segment owing to its benefits such as improved efficacy and a longer half-life in comparison with epoetin-alfa. NeoRecormon, developed by F. Hoffman-La Roche, is the first drug containing epoetin-beta as the active ingredient.
Darbepoetin-alfa is yet another novel erythropoietin drug developed by Amgen, Inc., which is marketed under the brand name Aranesp. The patent for this drug expires in 2024 in the U.S. Until this period, this drug enjoys patent exclusivity rights in the U.S. In Europe, the patent for Aranesp expired in 2020, due to which the sales of this drug have decreased in this region.
Darbepoetin-alfa is anticipated to witness positive growth in the future due to its cost-effectiveness, improved efficacy, and longer half-life. This is a viable solution for the treatment of anemia rising from end-stage renal diseases. Research is being undertaken for the discovery of new therapeutic areas for the application of darbepoetin-alfa, which is expected to serve this industry with growth potential.
Other medications such as epoetin-zeta and epoetin-omega are expected to exhibit a lucrative growth rate in the coming years. These are biosimilar formulations of epoetin-alfa but are more effective in the treatment of anemic conditions. EporatiobyTeva Pharmaceutical Industries, Ltd. and Mircera by F. Hoffmann-La Roche Ltd. are major products in this segment.
Renal diseases held a dominant share as prevalence of anemia is increasing at a constant rate. The first erythropoietin drug, Epogen was approved by the U.S. FDA for the treatment of anemic indications arising from CKD. Owing to early introduction of this drug for the treatment of CKD and rising incidence of the same, this segment dominated as of 2020.
The cancer segment is expected to be the fastest-growing segment owing to the increasing number of cancer incidence worldwide. Cancer chemotherapy involves the use of medication that reduces the RBC count amongst patients. As a result, usage of these alongside chemotherapy has become common in recent years. This has resulted in increasing demand for EPO drugs for cancer treatment, which augments growth.
The hematology segment is anticipated to witness steady growth over the forecast period due to rising R&D initiatives to develop cost-effective and viable solutions for treating conditions such as hypoxia and anemia of prematurity. Proper dosage of recombinant human erythropoietin can cure anemia of prematurity and reduces the need of multiple blood transfusion in neonates. This is expected to serve this industry with growth potential.
The neurology segment is expected to showcase growth over the forecast period as many of the erythropoietin drugs are considered to be an effective solution for treating neurological disorders such as Parkinson’s disease. Companies are involved in discovering new therapeutic areas for application of erythropoietin-stimulating agents, apart from the treatment of anemia. Major therapeutic research is being carried out for the neurology segment.
North America held a considerable share of erythropoietin drugs as of 2020 owing to increasing incidence of chronic diseases such as cancer, CKD, and HIV. According to the Centers for Disease Control and Prevention (CDC), 1.2 million people in the U.S. are living with HIV and 39,513 cases were diagnosed in 2015. These statistics indicate the need for EPO drugs over the forecast period.
In order to satisfy unmet needs, favorable reimbursement policies for HIV treatment are developed by the U.S. government. This would in turn provide a healthy platform for the growth of the North American EPO market. Furthermore, owing to the patent expiration of biologics, numerous new players have entered the market in this region and are undertaking various strategic steps to gain more revenue share. For instance, in October 2020, Teva Pharmaceutical Industries Ltd. acquired Anda, Inc., a leading distributor of generics in the U.S. from Allergan, plc., thereby strengthening its distribution network.
The Asia Pacific EPO industry is anticipated to grow at the fastest CAGR due to continuous rise in the incidence of chronic diseases coupled with high demand for low-cost therapeutics. Asia Pacific has attracted significant interest in many companies for the development of biosimilars and is known for developing more biosimilars, than anywhere else in the globe.
Moreover, increasing government initiatives to provide better health amenities to public in this region is another contributing factor for market growth. For instance, the Japanese government has passed a regulation to price biosimilars at a discount of 30% in comparison to making it available to people belonging to lower economic class at subsidized prices.
Global Erythropoietin drugs market report provides key statistics on the state of the trade and could be a valuable supply of steerage and direction for corporations and people curious about the market. The Erythropoietin drugs trade trends and promoting channels analysed. Erythropoietin drugs Market discovers numerous topics like regional market scope, product market numerous applications, market size consistent with specific product, sales and revenue by region, producing analysis, Industrial Chain, Market result Factors Analysis, market size forecast, and more. Finally, the practicableness of latest investment comes is evaluated and overall analysis conclusions offered.
Key Players
Johnson & Johnson; Celltrion, Inc.; Teva Pharmaceutical Industries Ltd.; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; LG Life Sciences Ltd.; Biocon Limited; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd.; and Dr. Reddy’s Laboratories Ltd.
Market Segmentation
Global Erythropoietin drugs Market: Drivers and Restrains
The analysis report has incorporated the analysis of various factors that augment the market’s growth. It constitutes trends, restraints, and drivers that remodel the market in either a positive or negative manner. This section additionally provides the scope of various segments and applications that may probably influence the market within the future. The elaborated info is predicated on current trends and historic milestones. This section additionally provides an analysis of the amount of production regarding the world market and regarding every kind from 2021-2030.
COVID-19 impact on the Erythropoietin drugs market
COVID-19 is associate communicable disease caused by the novel coronavirus. for the most part unknown before this happening across the world, COVID-19 has captive from a regional crisis to a worldwide pandemic in precisely a matter of a number of weeks. the world Health Organization (WHO) declared COVID-19 as an epidemic on March 11, 2021.
COVID-19 has compact most the industries across the world by disrupting provide chains and impeding numerous industrial operations. COVID-19-responsive measures undertaken by governments, like lockdown and social distancing, led to the closure of producing plants in the initial stage of the pandemic. With only a few industrial operations allowed, the demand for numerous input product within the industrial sector has declined considerably.
Key Highlights Involved in the Market Research Report: –
Erythropoietin drugs Market Study Coverage: It includes key market segments, key makers covered, the scope of product offered within the years thought of, world Erythropoietin drugs Market and study objectives. in addition, it touches the segmentation study provided within the report on the idea of the sort of product and applications.
Erythropoietin drugs Market executive Summary: This section emphasizes the key studies, market rate, competitive landscape, market drivers, trends, and problems additionally to the gross indicators.
Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/37913
Erythropoietin drugs Market Profile of Manufacturers: Analysis of every market player profiled is elaborated during this section. This section conjointly provides SWOT analysis, products, production, value, capacity, and different very important factors of the individual player.
The report delivers a comprehensive study of all the segments and shares info concerning the leading regions within the market. This report additionally states import/export consumption, offer and demand Figures, cost, business share, policy, price, revenue, and gross margins.
Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/37913
About Us: Vision Research Reports is unquestionably an expert in providing research reports on a diverse number of subjects including Alternative and Green Energy, Chemical, Energy, Glass, Machinery, Manufacturing, and Pharmaceuticals and Materials. We cater to distinguished MNCs, private equity firms, SMEs and Chinese companies pertaining to their market research data requirements.
We offer generic and amalgamated studies as well as customized studies to our clients based on their specific requirements. Our modus operandi constitutes of detailed and meticulous market surveys, company profiling, competitive landscaping and primary interviews. Our prudent insights have been vital in the inception of many investment programs, new project development programs, startups and technology breakthroughs.
Contact Us:
Call: +1 9197 992 333
Vision Research Reports
Any Assistance, Email – sales@visionresearchreports.com
Vision Research Report, Recently Announced New Report on "clinical trial biorepository & archiving solutions market …
Vision Research Report, Recently Announced New Report on "clinical trial kits market - Global Industry…
Vision Research Report, Recently Announced New Report on "surfing equipment market - Global Industry Analysis,…
Vision Research Report, Recently Announced New Report on "fusion biopsy market - Global Industry Analysis,…
Vision Research Report, Recently Announced New Report on "Flow Diverters market - Global Industry Analysis,…
Vision Research Report, Recently Announced New Report on "polymerase chain reaction market - Global Industry…